Results 171 to 180 of about 1,796 (202)

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) — diagnostic and therapeutic challenge

Hematology in Clinical Practice, 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive haematological malignancy. The disease usually affects the skin, bone marrow, peripheral blood and less commonly lymph nodes. The actual incidence of BPDCN is currently unknown.
Jarosław Wajs, Małgorzata Lewandowska, Przemysław Kluge, Lucyna Drążek, Dorota Jesionek-Kupnicka   +4 more
openaire   +1 more source

Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Current Hematologic Malignancy Reports, 2019
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive hematologic malignancy that has heterogeneous presentation and can involve the skin, lymph nodes, and bone marrow. Recent advancements in our patho-biologic understanding of the disease have led to the development of new targeted therapies for BPDCN.
David Rizzieri, Naveen Pemmaraju
exaly   +3 more sources

Biological Description of 109 Cases of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) from the French Network of BPDCN

Blood, 2015
Abstract Blastic plasmacytoid dendritic cell neoplasm is a clonal disease derived from precursors of plasmacytoid dendritic cells (pDC). It is a rare neoplasm involving the skin which may or may not be associated from the outset with a leukemic component.
Poret, Eve, Delettre, Fanny Angelot, Biichle, Sabeha, Roogy, Anne, Benazet, Louis, Pagadoy, Maider, Vidal, Chrystelle, Leroux, Franck, Harriverl, Veronique, Ferrand, Christophe, Salaun, Veronique, Benseddik, Zehaira, Guy, Julien, Jacob, Marie Christine, Roumier, Christophe, Feuillard, Jean, Vila, Liliana, Baseggio, Lucile, Plesa, Adriana, Arnoulet, Christine, Benet, B., Drénou, Bernard, Cannard, Veronique Latger, Béné, Marie-Christine, Ticchioni, Michel, Lusina, Daniel, Bardet, Valerie, Tavernier, Magalie L. E. Garff, Macintyre, Elizabeth, Asnafi, Vahid, Noguera, Maria Elena, Bouyer, Sabrina, Lafon, Carine Lecoq, Roussel, Mikael, Jardin, Fabrice, Solly, Françoise, Campos, Lydia, Galoisy, Anne, Arnaud, Anne, Daliphard, Sylvie, Geneviève, Franck, Lacroix, Romaric, Schillinger, Françoise, Seilles, Estelle, Binda, Delphine, Deconinck, Eric, Saas, Philippe, Ottou, Francine Garnache   +47 more
openaire   +2 more sources

Analysis of First-Year Twitter Metrics of a Rare Disease Community for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN

Current Hematologic Malignancy Reports, 2017
The use of Twitter, one of the most commonly engaged social media platforms in the world, is increasing among the general public. Notably, this trend has also been observed among those involved in the healthcare field. With its ability to readily connect diverse groups of stakeholders in a given area of interest, Twitter has become a focal point for ...
Naveen, Pemmaraju, Audun, Utengen, Vikas, Gupta, Michael A, Thompson, Andrew A, Lane   +4 more
openaire   +2 more sources

Role of tagraxofusp in treating blastic plasmacytoid dendritic cell neoplasm (BPDCN)

Expert Opinion on Biological Therapy, 2019
Introduction: Advances and drug development in rare diseases, such as blastic plasmacytoid dendritic cell neoplasm (BPDCN), has historically been limited by small numbers of patients in the target population. In recent years, the development of tagraxofusp (SL-401) (ELZONRIS, Stemline Therapeutics) for the treatment of adult and pediatric BPDCN has ...
Mansour Alfayez, Marina Konopleva, Naveen Pemmaraju   +2 more
openaire   +2 more sources

Outcomes of CNS involvement in blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Journal of Clinical Oncology, 2021
e19043 Background: BPDCN is rare cancer commonly involving the skin and marrow. Tagraxofusp (Tag), a CD123 targeted therapy, was the first FDA approved drug for BPDCN in 2018. CNS involvement occurs in 10-60% of patients and CNS staging and prophylactic (ppx) practices are variable.
Irl Brian Greenwell, James Davis, Hong Li, Deborah Soong, Justin Taylor, Andrew A. Lane, David Rizzieri   +6 more
openaire   +1 more source

Social Media and Internet Resources for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Current Hematologic Malignancy Reports, 2016
The incorporation of Internet resources and the use of social media among patients, clinicians, advocates, and researchers in the field of hematology and oncology are growing in importance. Utilization of online information sharing is rising, especially among those involved in rare blood cancer fields, which have generally featured a paucity of ...
Naveen Pemmaraju, Andrew A Lane
exaly   +4 more sources

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

Blood, 2022
Naveen Pemmaraju, Hagop Kantarjian, Joseph D. Khoury, Nitin Jain, Muzaffar H Qazilbash, Sanam Loghavi, Sherry A. Pierce, Keyur P. Patel, Guillermo Garcia-Manero, Elias Jabbour, Naval Daver, Gautam Borthakur, Marina Konopleva   +12 more
openaire   +1 more source

Blastic plasmacytoid dendritic cell neoplasm (BPDCN): the cutaneous sanctuary.

Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia, 2013
Blastic plasmacytoid dendritic cell neoplasm (BPDNC) is a rare tumour, which stems from plasmacytoid dendritic cells. Although the aetiology is still unclear, in the last few years various reports suggested a potential role of chromosomal aberrations in the oncogenesis.
A, Pileri, C, Delfino, V, Grandi, C, Agostinelli, S A, Pileri, N, Pimpinelli   +5 more
openaire   +1 more source

Uncovering Therapeutic Resistance in BPDCN through Single-Cell Transcriptome Profiling

Blood
Background: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, aggressive hematologic malignancy arising from plasmacytoid dendritic cells. The most commonly affected sites include the skin (65%), bone marrow (51%), and blood (45%).
Ji Ma, Qiang He, Qian Wu, Lili Feng, Y. Lynn Wang, Linna Xie   +5 more
openaire   +1 more source